Considering the recent advances in molecular imaging and currently available neuropathological biomarkers for Alzheimer’s disease (AD), i.e., CSF abeta, tau, ptau, and amyloid PET, the focus of this paper covers only a part of the comparative analyses that should be performed to outline a complete and cost-effective diagnostic algorithm. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.